Healthy
Conditions
Keywords
Safety, tolerability, pharmacokinetics, pharmacodynamics, ACZ885, Japanese,
Brief summary
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 administered via intravenous infusion and subcutaneous injection in healthy Japanese male volunteers.
Interventions
DRUGACZ885
Sponsors
Novartis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Japanese healthy male subjects age 20 to 45 years of age, and in good health * At screening and baseline, the subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis. * Body mass index within the range of 18 to 28 kg/m2 and weigh 50 to 100 kg
Exclusion criteria
* Smokers. * Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Acetaminophen is acceptable. Treatment of any biologics within three months prior to dosing. Having live vaccinations within six months prior to dosing. * Participation in any clinical investigation within 4 months prior to dosing. * Donation or loss of 400 mL or more of blood within 3 months; donation or loss of 200 mL or more of blood within 1 month; or donation of component blood within 2 weeks prior to participation. * Significant illness (sinusitis, pneumonia, cystitis, sepsis, etc) within two weeks prior to dosing. * A past personal or close family medical history of cardiac disorders * History of: * fainting, * low blood pressure when standing, * abnormal heart rhythms * acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated). * Clinically significant drug allergy or history and complication of atopic allergy (asthma, urticaria, eczematous dermatitis) * Known hypersensitivity to the study drug or similar drugs * Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or jeopardize participation in the study. * History of immunodeficiency diseases, including a positive HIV test result. * A positive Hepatitis B surface antigen (HBsAg), Hepatitis C or Syphilis test result. * Drug or alcohol abuse within the 12 months prior to dosing * Tuberculosis symptoms, complication of tuberculosis, contact with patients with suspected tuberculosis symptoms Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics and pharmacodynamics | — |
Countries
Japan
Outcome results
None listed